Novotech, a leading global full-service Contract Research Organization (CRO), has been honored with the 2024 Global Company of the Year Award by Frost & Sullivan. This prestigious accolade highlights Novotech’s dedication to enhancing clinical development for biotech firms through cutting-edge solutions, advanced analytics, and a broad international presence. The award acknowledges Novotech’s innovative full-service model, which accelerates clinical development by leveraging advanced analytics, diverse patient populations, and specialized technology.
“Novotech stands out in the ever-evolving CRO landscape by adeptly navigating the intricate regulatory environment with a deep understanding of local regulations and overcoming cultural challenges to position itself as a truly global CRO. Consequently, the company is on track to become a preferred global partner, showcasing regional leadership and localized expertise,” stated Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech’s extensive global presence allows it to deliver customized solutions that address the specific regulatory and cultural nuances of each market. This strategic advantage enhances patient recruitment speed and trial efficiency, driving successful outcomes for biotech clients. The company’s project manager-centric model ensures smooth communication and effective trial execution, fostering strong, collaborative client relationships.
Commitment to Innovation and Advanced Technology
A key factor in receiving this accolade is Novotech’s continued investment in cutting-edge technology to optimize clinical trial operations. The company’s use of artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly enhances data quality, trial planning, and stakeholder communication. Collaborations with industry leaders like Veeva and Medidata further empower Novotech’s clients to refine their drug development programs.
Recognition of Excellence
Since being first recognized as the best APAC CRO by Frost & Sullivan in 2006, Novotech has consistently earned this honor every year. The 2024 Global Company of the Year Award signifies Novotech’s ongoing commitment to improvement and its success in achieving optimal results for its partners and clients.
“We are thrilled to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition reflects the dedication of our team, our commitment to innovation, and our focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to lead the way in advancing clinical development and to be recognized as a top performer in the CRO industry.”
Frost & Sullivan’s Best Practices Awards honor companies across various global and regional markets for excellence in leadership, technological innovation, customer service, and strategic product development. Industry analysts assess market participants through in-depth interviews, analyses, and comprehensive secondary research to identify industry best practices.
